Oncology
Myxoid Liposarcoma
6
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Myxoid Liposarcoma is an early-stage landscape with 6 programs across 2 companies. The most active players are Takeda, Mario Negri Institute for Pharmacological Research. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 25
Phase 3
No programs
Analysis
Trial Status
5
clinical trials
Completed3 · 60%
Unknown status1 · 20%
Not yet recruiting1 · 20%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)